Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Amortizatization of Intangibles (2023 - 2025)

CG Oncology (CGON) has disclosed Amortizatization of Intangibles for 3 consecutive years, with -$951000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortizatization of Intangibles rose 24.22% year-over-year to -$951000.0, compared with a TTM value of $1.0 million through Dec 2025, down 79.69%, and an annual FY2025 reading of $1.0 million, down 79.69% over the prior year.
  • Amortizatization of Intangibles was -$951000.0 for Q4 2025 at CG Oncology, down from -$201000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $2.5 million in Q2 2024 and bottomed at -$1.3 million in Q4 2024.
  • Average Amortizatization of Intangibles over 3 years is $862400.0, with a median of $1.3 million recorded in 2023.
  • Peak annual rise in Amortizatization of Intangibles hit 37.33% in 2024, while the deepest fall reached 185.61% in 2024.
  • Year by year, Amortizatization of Intangibles stood at $1.5 million in 2023, then tumbled by 185.61% to -$1.3 million in 2024, then increased by 24.22% to -$951000.0 in 2025.
  • Business Quant data shows Amortizatization of Intangibles for CGON at -$951000.0 in Q4 2025, -$201000.0 in Q3 2025, and $1.9 million in Q2 2025.